Navigation Links
Robbins & Myers Reports Additional Gain and Increases Earnings Guidance
Date:4/2/2008

DAYTON, Ohio, April 2, 2008 /PRNewswire-FirstCall/ -- Robbins & Myers, Inc. (NYSE: RBN) today announced that certain contingency obligations relating to the sale of two of its Romaco product lines in fiscal year 2006 expired on March 31, 2008. As a result, the Company expects to recognize an additional pretax gain on that sale of approximately 3.5 million euros, or $5.4 million at current exchange rates, in its third fiscal quarter ending May 31, 2008.

This gain, which was not included in the Company's previously issued earnings guidance, is expected to increase diluted earnings per share (DEPS) for its third quarter and full year of fiscal 2008 by approximately $0.11 per share. Therefore, the Company increased its third quarter fiscal 2008 DEPS guidance from $0.42-$0.47 to $0.53 to $0.58 and its full year fiscal 2008 guidance from $1.82-$1.92 to $1.93-$2.03.

About Robbins & Myers

Robbins & Myers, Inc. is a leading supplier of engineered equipment and systems for critical applications in global energy, industrial, chemical and pharmaceutical markets.

In addition to historical information, this release contains forward- looking statements identified by use of words such as "expects," "anticipates," "believes," and similar expressions. These statements reflect management's current expectations and involve known and unknown risks, uncertainties, contingencies and other factors that could cause actual results, performance or achievements to differ materially from those stated. The most significant of these risks and uncertainties are described in our Form 10-K and Form 10-Q reports filed with the Securities and Exchange Commission and include, but are not limited to: a significant decline in capital expenditures in the specialty chemical and pharmaceutical industries; a major decline in oil and natural gas prices; foreign exchange rate fluctuations; work stoppages related to union negotiations; customer order cancellations; business disruptions caused by the implementation of business computer systems; our ability to comply with the financial covenants and other provisions of our financing arrangements; events or circumstances which result in an impairment of assets; the potential impact of U.S. and foreign legislation, government regulations, and other governmental action, including those relating to export and import of products and materials, and changes in the interpretation and application of such laws and regulations; the outcome of audit, compliance, administrative or investigatory reviews; and general economic conditions that can affect demand in the process industries. Except as otherwise required by law, we do not undertake any obligation to publicly update or revise these forward- looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE Robbins & Myers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
2. Robbins & Myers Announces Regular Quarterly Cash Dividend
3. Robbins Bros. Gives Water at AIDS Walk L.A.
4. Robbins & Myers Presenting at Bear Stearns 3rd Annual Commodities and Capital Goods Conference November 28, 2007
5. Robbins & Myers to Present at Merrill Lynch Growth Industrials Conference December 13, 2007
6. Robbins & Myers to Present at Gabelli Conference
7. Robbins & Myers Schedules Second Quarter Fiscal 2008 Financial Results Conference Call
8. Bristol-Myers Squibb Announces Dividend
9. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
10. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
11. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson University , ... was awarded a $300,000 grant from The Pew Center for Arts & Heritage ... and the recognition of one’s own limits among health professions students. , ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) ... of life a decade after surgery, though activity levels decline over time. The ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... ORLANDO, Fla. , July 17, 2017  MedX ... - branded medical testing, strengthening and rehabilitation equipment, today ... Back Machine Program. MedX is considered the gold standard ... world leader in specialized medical strengthening equipment. ... into a lease with the physician or practice who ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company ... agreement with generic companies to resolve pending patent litigation in ... Virginia regarding the Cialis ® (tadalafil) ... on April 26, 2020. As part of the agreement, Cialis ... September 27, 2018. "The unit dose patent for ...
Breaking Medicine Technology: